Zevra Therapeutics Files 8-K on Financials
Ticker: ZVRA · Form: 8-K · Filed: Aug 13, 2024 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: ZEVRA
TL;DR
Zevra Therapeutics dropped an 8-K on August 13th about their financials. Check it out.
AI Summary
On August 13, 2024, Zevra Therapeutics, Inc. filed an 8-K report detailing its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747.
Why It Matters
This filing provides investors with an update on Zevra Therapeutics' financial performance and condition, which is crucial for evaluating the company's stability and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain any new material events or significant negative news.
Key Players & Entities
- Zevra Therapeutics, Inc. (company) — Registrant
- August 13, 2024 (date) — Date of Report
- 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747 (address) — Principal Executive Offices
- Kempharm, Inc (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Zevra Therapeutics, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on August 13, 2024.
What is Zevra Therapeutics, Inc.'s principal executive office address?
Zevra Therapeutics, Inc.'s principal executive office is located at 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747.
Has Zevra Therapeutics, Inc. operated under any former names?
Yes, Zevra Therapeutics, Inc. formerly operated under the name Kempharm, Inc.
Under which state was Zevra Therapeutics, Inc. incorporated?
Zevra Therapeutics, Inc. was incorporated in Delaware.
Filing Stats: 563 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-08-13 16:17:16
Key Financial Figures
- $0.0001 — ch registered Common Stock , par value $0.0001 per share ZVRA The Nasdaq Stock Mark
Filing Documents
- zvra20240520_8k.htm (8-K) — 33KB
- ex_676970.htm (EX-99.1) — 193KB
- zvralogo.jpg (GRAPHIC) — 6KB
- 0001437749-24-026397.txt ( ) — 383KB
- zvra-20240813.xsd (EX-101.SCH) — 3KB
- zvra-20240813_def.xml (EX-101.DEF) — 11KB
- zvra-20240813_lab.xml (EX-101.LAB) — 15KB
- zvra-20240813_pre.xml (EX-101.PRE) — 11KB
- zvra20240520_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition . On August 13, 2024, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the second quarter ended June 30, 2024, as well as information regarding a conference call and live audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, August 13, 2024, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in the press release, furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of Zevra's filings under the Securities Act of 1933, as amended, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 13, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Zevra Therapeutics, Inc . Date: August 13, 2024 By: /s/ Timothy J. Sangiovanni Timothy J. Sangiovanni, CPA Senior Vice President, Finance and Corporate Controller